[Edaily Reporter Hong Ju-yeon ] #LivsMed Inc., an innovator in surgical robots and minimally invasive surgical instruments, has begun the process of obtaining domestic approval for its entire product lineup, ranging from laparoscopic surgical instruments to high-end surgical instruments and next-generation surgical robots. LivsMed Inc.’s next-generation surgical robot platform, “STARK™.” (Image courtesy of LivsMed Inc.) LivsMed Inc. announced on the 7th that it has applied for product approval from the Ministry of Food and Drug Safety (MFDS) for its next-generation surgical robot platform, “STARK™.”
STARK is a purely domestically developed next-generation surgical robot based on LivsMed Inc.’s proprietary core technologies. Its flagship product, “ArtiSential™,” has proven its technical capabilities through use in over 300,000 cumulative surgeries in clinical settings both domestically and internationally. STARK not only extends the multi-joint end-tool technology of ArtiSential—which allows for movement in all directions—to a robotic platform but is also expected to possess unparalleled competitiveness as it incorporates all of the core technologies the company has accumulated over the years.
LivsMed Inc. covers the entire spectrum of handheld products for minimally invasive surgery with its proprietary technology, including ArtiSential™, the vascular sealing device “ArtiSeal™,” the surgical stapler “ArtiStapler™,” and the laparoscopic camera system “LivsCAM™.” Through Stark, the company is poised to become the world’s first “full-spectrum” company to also offer surgical robots.
Stark is the first robotic system to achieve the highest level of multi-joint performance (90 degrees in all directions) in the instrument lineup inserted into the human body to perform surgical procedures. The robotic arm system is also designed with a compact and flexible modular structure to adapt flexibly not only to existing operating rooms but also to future environmental changes. LivsMed Inc. defines the flexibility of these instruments and robotic arm systems under the keyword “Freedom of Performance” and has embodied this concept in Stark.
Lee Jeong-ju, CEO of LivsMed Inc., stated, “Stark aims to redefine the very standard for surgical robots with outstanding functionality and a reasonable price,” adding, “We are now embarking in earnest on this ambitious challenge.”
KBI METAL CO., LTD.’s Eumseong Plant Office Building. (Photo courtesy of KBI Group)
KBI METAL CO., LTD. posted its highest-ever cumulative operating profit for the first three quarters of this year,…
“Please continue to look favorably upon our Shenyang Oak Soju.”This is a handwritten message posted by Cho Woong-rae, Chairman of Seonyang Soju, on his Instagram on the 12th. In his handwritten messag…
Resolute announced to the U.S. Securities and Exchange Commission (SEC) on the 14th (local time) that it had completed patient enrollment for the Phase 3 clinical trial of “Ersodetug.” (Source: U.S. S…